Table 3 Manufacturers and accuracy of RDTs among included studies
First author | Manufacturer | Sample size | TP | FP | TN | FN | SE | SP |
|---|---|---|---|---|---|---|---|---|
Montbugnoil et al. | Anti-HCV Ab rapid test (1st IRP 75/537 by Thema Ricerca, WHO Geneva) | 100 | 50 | 1 | 49 | 0 | 100% | 98% |
O’Connell, R. J. et al. | Axiom (Axiom Diagnostics, Burstadt,Germany) | 674 | 326 | 10 | 329 | 9 | 97% | 97% |
O’Connell, R. J. et al. | Axiom (Axiom Diagnostics, Burstadt,Germany) | 168 | 77 | 2 | 82 | 7 | 92% | 98% |
O’Connell, R. J. et al. | Axiom (Axiom Diagnostics, Burstadt,Germany) | 168 | 82 | 5 | 79 | 2 | 98% | 94% |
Scalioni Lde, P et al. | Bioeasy HCV Rapid Test, (Bioeasy Diagnóstica Ltd., Brazil) | 194 | 137 | 0 | 48 | 9 | 94% | 100% |
Scalioni Lde, P et al. | Bioeasy HCV Rapid Test (Bioeasy Diagnóstica Ltd., Brazil) | 194 | 111 | 0 | 48 | 35 | 76% | 100% |
Scalioni Lde, P et al. | Bioeasy HCV Rapid Test (Bioeasy Diagnóstica Ltd., Brazil) | 194 | 136 | 0 | 48 | 10 | 93% | 100% |
Jewett, A et al. | Chembio DPP HCV Test (Chembio Diagnostic Systems, USA) | 407 | 101 | 3 | 290 | 8 | 93% | 99% |
Jewett, A et al. | Chembio DPP HCV test (Chembio Diagnostic Systems,USA) | 400 | 88 | 3 | 294 | 15 | 85% | 99% |
Smith, B. D et al. | Chembio DPP HCV test (Chembio Diagnostic Systems, USA) | 476 | 308 | 12 | 125 | 32 | 91% | 91% |
Smith, B. D et al. | Chembio DPP HCV test (Chembio Diagnostic Systems, USA) | 385 | 264 | 3 | 101 | 17 | 94% | 97% |
Smith et al. et al. | Chembio DPP HCV test (Chembio Diagnostic Systems, USA) | 1081 | 525 | 1 | 543 | 12 | 98% | 100% |
O’Connell, R. J. et al. | CORE (CORE Diagnostics, United Kingdom) | 168 | 29 | 1 | 83 | 55 | 35% | 99% |
O’Connell, R. J et al. | CORE (CORE Diagnostics, United Kingdom) | 168 | 24 | 2 | 82 | 60 | 29% | 98% |
O’Connell, R. J et al. | CORE (CORE Diagnostics, United Kingdom) | 674 | 323 | 7 | 332 | 12 | 96% | 98% |
Maity et al. | Diagnostics Ltd. (other information is not available) | 300 | 132 | 0 | 168 | 0 | 100% | 100% |
O’Connell, R. J. et al. | FirstVue (AT First Diagnostic, Woodbury,NY, USA) | 168 | 66 | 0 | 84 | 18 | 79% | 100% |
O’Connell, R. J. et al. | FirstVue (AT First Diagnostic, Woodbury,NY, USA) | 168 | 54 | 1 | 83 | 30 | 64% | 99% |
O’Connell, R. J. et al. | FirstVue (AT First Diagnostic, Woodbury,NY, USA) | 674 | 312 | 3 | 336 | 23 | 93% | 99% |
Al-Tahish et al. | Fourth- generation HCV TRI_DOT (J. Mitra Co, India) | 100 | 34 | 15 | 50 | 1 | 97% | 77% |
Daniel et al. | Fourth- generation HCV TRI_DOT (J. Mitra Co, India) | 2590 | 138 | 24 | 2427 | 1 | 99% | 99% |
Kim, M. H. et al. | GENEDIA® HCV Rapid LF (Green Cross medical science corp., Korea) | 100 | 52 | 0 | 34 | 14 | 79% | 100% |
Kaur et al. | HCV Bidot (J. Mitra Co., India) | 2754 | 28 | 0 | 2722 | 4 | 88% | 100% |
Al-Tahish | HCV one step test device (ACON Laboratories, USA) | 100 | 34 | 15 | 50 | 1 | 97% | 77% |
Ivantes et al. | HCV Rapid Test Bioeasy (Bioeasy Diagnostica Ltd., Brazil) | 71 | 30 | 3 | 38 | 0 | 100% | 93% |
da Rosa et al. | HCV Rapid Test Bioeasy® (Standard Diagnostics, South Korea) | 307 | 100 | 0 | 204 | 3 | 97% | 100% |
Poovoran et al. | HCV-SPOT assay (Genelabs Diagnostics Pty Ltd., Singapore) | 192 | 41 | 11 | 139 | 1 | 98% | 93% |
Mvere et al. | HCV-SPOT assay (Genelabs Diagnostics Pty Ltd., Singapore) | 206 | 10 | 4 | 191 | 1 | 91% | 98% |
Njouom et al. | Hexagon® HCV (Not reported manufacturer located country) | 329 | 160 | 17 | 151 | 1 | 99% | 90% |
Al-Tahish et al. | ImmunoComb II HCV (Inverness Medical Innovations, USA) | 100 | 34 | 14 | 51 | 1 | 97% | 78% |
Yarri et al. | ImmunoComb II HCV (Inverness Medical Innovations, USA) | 37 | 18 | 4 | 15 | 0 | 100% | 79% |
Yarri et al. | ImmunoComb II HCV (Inverness Medical Innovations, USA) | 37 | 18 | 1 | 18 | 0 | 100% | 95% |
Njouom et al. | ImmunoComb® II HCV assay (Orgenics Ltd., not reported manufacturer located country) | 329 | 103 | 0 | 168 | 58 | 64% | 100% |
da Rosa et al. | Imuno-Rapido HCV® (Wama Diagnostica, Brazil). | 307 | 100 | 0 | 204 | 3 | 97% | 100% |
O’Connell, R. J. et al. | Instant View Cassette (Alfa Scientific Designs, Poway, CA, USA) | 674 | 321 | 3 | 336 | 14 | 96% | 99% |
O’Connell, R. J. et al. | Instant View Cassette (Alfa Scientific Designs, Poway, CA, USA) | 168 | 68 | 3 | 81 | 16 | 81% | 96% |
O’Connell, R. J. et al. | Instant View Cassette (Alfa Scientific Designs, Poway, CA, USA) | 168 | 46 | 1 | 83 | 38 | 55% | 99% |
Maity et al. | J Mitra Co. India other information is not available) | 300 | 120 | 0 | 174 | 6 | 95% | 100% |
Jewett, A et al. | Rapid HIV/HCV antibody test (Medmira Laboratories, Canada) | 374 | 80 | 0 | 274 | 20 | 80% | 100% |
Nyirenda et al. | Monoelisa HCV Ag/Ab ultra-microplate EIA (Bio-Rad, France) | 202 | 2 | 7 | 186 | 7 | 22% | 96% |
Tagny et al. | Monolisa HCV Ag-Ab Ultra, (BioRad, France) | 1998 | 26 | 28 | 1929 | 15 | 63% | 99% |
Smith et al. | Multiplo Rapid HIV/HCV Antibody Test (MedMira, Canada) | 1081 | 474 | 1 | 543 | 63 | 88% | 100% |
Smith, B. D et al. | Multiplo Rapid HIV/HCV Antibody Test (MedMira, Canada) | 432 | 303 | 8 | 40 | 81 | 79% | 83% |
Cha, Y. J. et al. | OraQuick (OraSure Technologies, PA USA) | 437 | 134 | 0 | 300 | 3 | 98% | 100% |
Cha, Y. J. et al. | Architect (Abbott Laboratories, Abbott Park, IL, USA) | 400 | 200 | 0 | 200 | 0 | 100% | 100% |
Lee, S. R et al. | OraQuick (OraSure Technologies, PA USA) | 2183 | 756 | 1 | 1422 | 1 | 100% | 100% |
Lee, S. R et al. | OraQuick (OraSure Technologies, PA USA) | 2183 | 755 | 2 | 1420 | 1 | 100% | 100% |
Lee, S. R et al. | OraQuick (OraSure Technologies, PA USA) | 2183 | 753 | 2 | 1421 | 2 | 100% | 100% |
Lee, S. R et al. | OraQuick (OraSure Technologies, PA USA) | 2183 | 752 | 1 | 1421 | 2 | 100% | 100% |
Lee, S. R et al. | OraQuick (OraSure Technologies, PA USA) | 2183 | 739 | 5 | 1418 | 14 | 98% | 100% |
O’Connell, R. J et al. | OraQuick (OraSure Technologies, PA USA) | 674 | 333 | 1 | 338 | 2 | 99% | 100% |
O’Connell, R. J et al. | OraQuick (OraSure Technologies, PA USA) | 168 | 83 | 1 | 83 | 1 | 99% | 99% |
O’Connell, R. J et al. | OraQuick (OraSure Technologies, PA USA) | 168 | 82 | 0 | 84 | 2 | 98% | 100% |
Smith, B. D et al. | OraQuick (OraSure Technologies, PA USA) | 549 | 375 | 8 | 140 | 26 | 94% | .95% |
Smith, B. D et al. | OraQuick (OraSure Technologies, PA USA) | 266 | 188 | 1 | 72 | 5 | 97% | 99% |
Lee et al. | OraQuick (OraSure Technologies, PA USA) | 572 | 122 | 0 | 449 | 1 | 99% | 100% |
Lee et al. | OraQuick (OraSure Technologies, PA USA) | 572 | 123 | 0 | 449 | 0 | 100% | 100% |
Lee et al. | OraQuick (OraSure Technologies, PA USA) | 572 | 123 | 0 | 449 | 0 | 100% | 100% |
Lee et al. | OraQuick (OraSure Technologies, PA USA) | 572 | 123 | 1 | 448 | 0 | 100% | 100% |
Lee et al. | OraQuick (OraSure Technologies, PA USA) | 572 | 123 | 1 | 448 | 0 | 100% | 100% |
Smith et al. | OraQuick (OraSure Technologies, PA USA) | 1081 | 533 | 3 | 541 | 4 | 99% | 99% |
Drobnik et al. | OraQuick (OraSure Technologies, PA USA) | 484 | 92 | 3 | 382 | 7 | 93% | 99% |
Stephen R. Lee et al. | OraQuick (OraSure Technologies, PA USA) | 2180 | 756 | 1 | 1422 | 1 | 100% | 100% |
Stephen R. Lee et al. | OraQuick (OraSure Technologies, PA USA) | 2178 | 755 | 2 | 1420 | 1 | 100% | 100% |
Stephen R. Lee et al. | OraQuick (OraSure Technologies, PA USA) | 2178 | 753 | 2 | 1421 | 2 | 100% | 100% |
Stephen R. Lee et al. | OraQuick (OraSure Technologies, PA USA) | 2176 | 752 | 1 | 1421 | 2 | 100% | 100% |
Stephen R. Lee et al. | OraQuick (OraSure Technologies, PA USA) | 2176 | 739 | 5 | 1418 | 14 | 98% | 100% |
Gao et al. | OraQuick (OraSure Technologies, PA USA) | 1156 | 16 | 6 | 1133 | 1 | 94% | 99% |
Ibrahim | OraQuick (OraSure Technologies, PA USA) | 160 | 53 | 0 | 100 | 7 | 88% | 100% |
Scalioni Lde, P_2014 | OraQuick (OraSure Technologies, PA USA) | 172 | 108 | 0 | 50 | 14 | 89% | 100% |
Hess et al. | DPP HIV-HCV-Syphilis Assay (Chembio Diagnostic Systems, Inc., Medford, NY). | 948 | 152 | 6 | 776 | 14 | 92% | 99% |
Buti et al. | Not available | 188 | 135 | 0 | 50 | 3 | 98% | 100% |
Yuen et al. | SM-HCV Rapid Test (SERO-Med Laborspezialita¨ten GmbH, Eichsta ¨tt, Germany) | 290 | 98 | 0 | 189 | 3 | 97% | 100% |
Maity et al. | SPAN Diagnostics, Indi, other information is not available | 300 | 132 | 0 | 168 | 0 | 100% | 100% |
Kant et al. | Toyo anti-HCV test (Turklab, Izmir, Turkey) | 185 | 82 | 12 | 90 | 1 | 99% | 88% |
Kosack, C. S. et al. | The ImmunoFlow HCV test (Core Diagnostics,United Kingdom) | 82 | 55 | 0 | 26 | 0 | 100% | 100% |
Scalioni Lde et al. | WAMA Imuno-Rápido HCV Kit (WAMA Diagnóstica, Brazil) | 194 | 119 | 3 | 45 | 27 | 82% | 94% |
Scalioni Lde, P et al. | WAMA Imuno-Rápido HCV Kit (WAMA Diagnóstica, Brazil) | 194 | 134 | 3 | 45 | 12 | 92% | 94% |
Hui et al. | Not reported | 197 | 91 | 0 | 88 | 18 | 83% | 100% |